359 related articles for article (PubMed ID: 19562604)
1. The fertility-sparing treatment in patients with endometrial atypical hyperplasia and early endometrial cancer: a debated therapeutic option.
Gadducci A; Spirito N; Baroni E; Tana R; Genazzani AR
Gynecol Endocrinol; 2009 Oct; 25(10):683-91. PubMed ID: 19562604
[TBL] [Abstract][Full Text] [Related]
2. [Outcome analysis of conservative treatment of well-differentiated endometrial adenocarcinoma and severe atypical hyperplasia in young women].
Yu M; Shen K; Yang JX; Huang HF; Wu M; Pan LY; Lang JH; Lian LJ
Zhonghua Fu Chan Ke Za Zhi; 2006 Apr; 41(4):242-5. PubMed ID: 16759458
[TBL] [Abstract][Full Text] [Related]
3. [Pregnant rate and pregnancy-relating factors of patients with early endometrial carcinoma and severe atypical hyperplasia of endometrium after fertility-preserving treatment by progestin].
Cao DY; Yu M; Yang JX; Shen K; Huang HF; Cheng NH; Sun ZY; Deng CY; Yu Q; He FF
Zhonghua Fu Chan Ke Za Zhi; 2013 Jul; 48(7):519-22. PubMed ID: 24284224
[TBL] [Abstract][Full Text] [Related]
4. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women.
Ushijima K; Yahata H; Yoshikawa H; Konishi I; Yasugi T; Saito T; Nakanishi T; Sasaki H; Saji F; Iwasaka T; Hatae M; Kodama S; Saito T; Terakawa N; Yaegashi N; Hiura M; Sakamoto A; Tsuda H; Fukunaga M; Kamura T
J Clin Oncol; 2007 Jul; 25(19):2798-803. PubMed ID: 17602085
[TBL] [Abstract][Full Text] [Related]
5. Increased natural killer cells and decreased regulatory T cells are seen in complex atypical endometrial hyperplasia and well-differentiated carcinoma treated with progestins.
Witkiewicz AK; McConnell T; Potoczek M; Emmons RV; Kurman RJ
Hum Pathol; 2010 Jan; 41(1):26-32. PubMed ID: 19733383
[TBL] [Abstract][Full Text] [Related]
6. Fertility-preserving treatment with progestin, and pathological criteria to predict responses, in young women with endometrial cancer.
Yamazawa K; Hirai M; Fujito A; Nishi H; Terauchi F; Ishikura H; Shozu M; Isaka K
Hum Reprod; 2007 Jul; 22(7):1953-8. PubMed ID: 17449880
[TBL] [Abstract][Full Text] [Related]
7. Fertility-preserving treatment in young women with well-differentiated endometrial carcinoma and severe atypical hyperplasia of endometrium.
Yu M; Yang JX; Wu M; Lang JH; Huo Z; Shen K
Fertil Steril; 2009 Dec; 92(6):2122-4. PubMed ID: 19591991
[TBL] [Abstract][Full Text] [Related]
8. Fertility-sparing treatment of endometrial cancer precursors among young women: a reproductive point of view.
Ricciardi E; Maniglio P; Frega A; Marci R; Caserta D; Moscarini M
Eur Rev Med Pharmacol Sci; 2012 Dec; 16(14):1934-7. PubMed ID: 23242719
[TBL] [Abstract][Full Text] [Related]
9. Fertility-sparing treatment in young women with endometrial cancer or atypical complex hyperplasia: a prospective single-institution experience of 21 cases.
Signorelli M; Caspani G; Bonazzi C; Chiappa V; Perego P; Mangioni C
BJOG; 2009 Jan; 116(1):114-8. PubMed ID: 19087082
[TBL] [Abstract][Full Text] [Related]
10. Conservative management of young patients with endometrial highly-differentiated adenocarcinoma.
Kalogiannidis I; Agorastos T
J Obstet Gynaecol; 2011; 31(1):13-7. PubMed ID: 21280986
[TBL] [Abstract][Full Text] [Related]
11. Reevaluating the safety of fertility-sparing hormonal therapy for early endometrial cancer.
Yang YC; Wu CC; Chen CP; Chang CL; Wang KL
Gynecol Oncol; 2005 Nov; 99(2):287-93. PubMed ID: 16051341
[TBL] [Abstract][Full Text] [Related]
12. Progestin re-treatment in patients with recurrent endometrial adenocarcinoma after successful fertility-sparing management using progestin.
Park JY; Lee SH; Seong SJ; Kim DY; Kim TJ; Kim JW; Kim JH; Kim YM; Kim YT; Bae DS; Nam JH
Gynecol Oncol; 2013 Apr; 129(1):7-11. PubMed ID: 23283299
[TBL] [Abstract][Full Text] [Related]
13. Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin.
Simpson AN; Feigenberg T; Clarke BA; Gien LT; Ismiil N; Laframboise S; Massey C; Ferguson SE
Gynecol Oncol; 2014 May; 133(2):229-33. PubMed ID: 24561246
[TBL] [Abstract][Full Text] [Related]
14. The role of hormones for the treatment of endometrial hyperplasia and endometrial cancer.
Lai CH; Huang HJ
Curr Opin Obstet Gynecol; 2006 Feb; 18(1):29-34. PubMed ID: 16493257
[TBL] [Abstract][Full Text] [Related]
15. Occult myometrial recurrence after progesterone therapy to preserve fertility in a young patient with endometrial cancer.
Hurst SA; Hartzfeld KM; Del Priore G
Fertil Steril; 2008 Mar; 89(3):724.e1-3. PubMed ID: 17570366
[TBL] [Abstract][Full Text] [Related]
16. [Conservative treatment of endometrial cancer as a way to preserve fertility. Five-year experience at Instituto Nacional de Perinatilogía Isidro Espinoza de los Reyes].
Arteaga Gómez AC; Castellanos Barroso G; Márquez Acosta G
Ginecol Obstet Mex; 2012 Jun; 80(6):394-9. PubMed ID: 22826967
[TBL] [Abstract][Full Text] [Related]
17. Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins.
Wheeler DT; Bristow RE; Kurman RJ
Am J Surg Pathol; 2007 Jul; 31(7):988-98. PubMed ID: 17592264
[TBL] [Abstract][Full Text] [Related]
18. [Young women with atypical endometrial hyperplasia or endometrial adenocarcinoma stage I: will conservative treatment allow pregnancy? Results of a French multicentric survey].
Le Digabel JF; Gariel C; Catala L; Dhainaut C; Madelenat P; Descamps P
Gynecol Obstet Fertil; 2006 Jan; 34(1):27-33. PubMed ID: 16406735
[TBL] [Abstract][Full Text] [Related]
19. Development of metastatic endometrial endometrioid adenocarcinoma while on progestin therapy for endometrial hyperplasia.
Rubatt JM; Slomovitz BM; Burke TW; Broaddus RR
Gynecol Oncol; 2005 Nov; 99(2):472-6. PubMed ID: 16099019
[TBL] [Abstract][Full Text] [Related]
20. Sparing fertility in young patients with endometrial cancer.
Chiva L; Lapuente F; González-Cortijo L; Carballo N; García JF; Rojo A; Gonzalez-Martín A
Gynecol Oncol; 2008 Nov; 111(2 Suppl):S101-4. PubMed ID: 18804267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
